1 Introduction 1
1.1 Dry powder inhalers 2
1.1.1 Classical pulmonary powder formulations 4
1.1.2 Innovative pulmonary powder formulations 6
1.2 Deep lung delivery of biopharmaceuticals 8
1.2.1 Anatomy and physiology of the lung 9
1.2.2 Pulmonary resorption mechanisms for macromolecules 10
1.3 Formulation challenges: biopharmaceuticals in DPIs 12
1.3.1 Structure and instabilities of biopharmaceuticals 12
1.3.1.1 Physical instability of biopharmaceuticals 13
1.3.1.2 Chemical instability of biopharmaceuticals 15
1.3.1.3 Stabilization of liquid biopharmaceuticals 15
1.3.1.4 Stabilization of solid state biopharmaceuticals 16
1.3.2 Producing pulmonary applicable biopharmaceutical powders 18
1.3.2.1 Requirements on particle size for pulmonary application 18
1.3.2.2 Spray-drying 20
1.3.3 Flow properties of inhalable biopharmaceutical powders 28
1.3.3.1 Static and dynamic angle of repose 29
1.3.3.2 Vibrating spatula 33
1.3.3.3 Shear testing 37
1.3.3.4 Comparison of different methods for the determination of flow properties of pulmonary applicable powders 46
2 Objectives of this thesis 47
3 Materials and methods 49
3.1 Materials 49
3.1.1 Human serum albumin (HSA) 49
3.1.2 Type 1 immunoglobulin G (IgG1) 49
3.1.3 Dextran 1 (Dx1) 50
3.1.4 Lactosucrose 51
3.1.5 Coupling sugar 51
3.1.6 Compatible solutes 53
3.1.7 Excipients and reagents 54

3.2 Methods 55
3.2.1 Sugar analytics 55
3.2.1.1 Freeze-drying 55
3.2.1.2 Electrospray ionization mass spectroscopy (ESI-MS) 56
3.2.1.3 High performance liquid chromatography (HPLC) 56
3.2.2 Producing protein DPIs 57
3.2.2.1 Preparation of spray-drying solutions 57
3.2.2.2 Spray-drying (sd) 57
3.2.3 Material properties – physicochemical characterization 58
3.2.3.1 Differential scanning calorimetry (DSC) 58
3.2.3.2 X-ray powder diffractometry (XRD) 58
3.2.3.3 Karl-Fischer titration 59
3.2.4 DPI particles – physicochemical characterization 59
3.2.4.1 Laserdiffractometry (LD) 59
3.2.4.2 Anderson Cascade Impactor (ACI) 59
3.2.4.3 Time of flight measurement (TOF) 60
3.2.4.4 HandiHaler® 61
3.2.4.5 Scanning electron microscopy (SEM) 62
3.2.5 Flow properties (FP) of spray-dried powders 63
3.2.5.1 Powder flow analyzer (PFA) 63
3.2.5.2 Rotational shear tester (RST) 64
3.2.6 Protein stability 66
3.2.6.1 Spray-drying process stability screening 66
3.2.6.2 Vacuum-drying process stability screening 66
3.2.6.3 Equilibration process stability screening 66
3.2.6.4 Stress storage stability screening 66
3.2.6.5 Dry short-term storage stability screening 66
3.2.6.6 Equilibrated short-term storage stability screening 67
3.2.6.7 Dry long-term storage stability screening 67
3.2.6.8 Humid long-term storage stability screening 67
3.2.7 Protein analytics 68
3.2.7.1 Size exclusion high performance liquid chromatography 68
3.2.7.2 Turbidimetry 68

4 Results and Discussion 70

4.1 Quest for innovative sd excipients 70

4.1.1 New sugars 71

4.1.1.1 Dextran 1 71

4.1.1.2 Lactosucrose and Coupling Sugar 72

4.1.2 Compatible solutes 73

4.1.3 Additives 74

4.1.3.1 Amino acids 74

4.1.3.2 Tri-peptides 75

4.2 Sugar analytics 77

4.2.1 Electrospray ionization mass spectrometry (ESI-MS) 77

4.2.2 Differential scanning calorimetry 79

4.2.3 HPLC-analysis of sugars 80

4.2.3.1 Ion-exchange HPLC 80

4.2.3.2 Amino bonded silica gel HPLC 82

4.2.4 Summary 87

4.3 Sd studies of new excipient formulations 88

4.3.1 Sd of non protein formulations 88

4.3.2 Sd of sugar/HSA formulations 89

4.3.3 Sd of sugar/citrulline formulations 91

4.3.4 Sd of sugar/Ile/HSA formulations 92

4.3.5 Sd of sugar/IgG1 formulations 94

4.3.6 Sd of various excipient to IgG1 ratios 96

4.3.7 Sd of sugar isoleucine IgG1 formulations 96

4.3.8 Sd of sugar/citrulline/IgG1 formulations 98

4.3.9 Sd of compatible solutes/IgG1 formulations 99

4.3.10 Sd of compatible solutes Ile IgG1 formulations 100

4.3.11 Summary 101

4.4 Protein stabilizing capabilities of new excipients 103

4.4.1 Process stability of new IgG1 formulations 103

4.4.2 Stress storage stability testing of new IgG1 formulations 105

4.4.3 Short-term stability testing of new IgG1 formulations 109

4.4.4 Summary 117

4.5 Development of Dextran 1 containing IgG1 DPIs 119
4.5.1 Aerodynamic performance (AP) 119
4.5.1.1 Effect of total solid concentration and HE-cyclone on AP 119
4.5.1.2 Effect of Isoleucine on AP 121
4.5.1.3 Effect of Dextran 1 to Isoleucine Ratio on AP 122
4.5.1.4 Effect of Tri-Isoleucine on the AP 124
4.5.1.5 Effect of relative humidity on AP 126
4.5.2 Protein stability 128
4.5.2.1 Effect of TS on protein sd stability 128
4.5.2.2 Influence of formulation on sd and stress storage stability 129
4.5.2.3 Long term stability testing 130
4.5.3 Summary 133
4.6 Development of Lactosucrose containing IgG1 DPIs 135
4.6.1 Aerodynamic performance 135
4.6.1.1 Effect of HE-cyclone, AAF and TS on AP 135
4.6.1.2 Effect of Ile and Ile3 on AP of sd LS/IgG1 formulations 137
4.6.1.3 Effect of LS - Ile3 ratio on AP of LS/IgG1 powders 139
4.6.1.4 Effect of relative humidity on the AP of LS/Ile3/IgG1 powders 140
4.6.2 Protein stability 144
4.6.2.1 Effect of formulation and TS on protein sd stability 144
4.6.2.2 Influence of formulation on stress storage stability 146
4.6.2.3 Long term stability testing 147
4.6.3 Summary 154
4.7 Flow-properties of new protein-DPIs 157
4.7.1 Powder Flow Analyzer (PFA) 157
4.7.2 Peschl Rotation Shear Tester (RST) 158
4.7.2.1 FP quantification of sd IgG1 Formulations by shear testing 158
4.7.2.2 Influence of the Cyclone on FP 160
4.7.2.3 Influence of Ile and Ile3 content on FP 161
4.7.3 Summary 165
5 Final Summary 166